MRNS / Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the develop more_horizontal

Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline more_horizontal

Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mig more_horizontal

Marinus (NASDAQ:MRNS) Pharmaceuticals Inc shares climbed 20% to $7.02 on Tuesday after the pharmaceutical company dedicated to the development of ther more_horizontal

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therap more_horizontal

Marinus Pharmaceuticals (MRNS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate rev more_horizontal

Marinus Pharmaceuticals has pivoted from postpartum depression to focus on seizure disorders, leading to FDA approval for Ztalmy (ganaxolone) for trea more_horizontal

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares more_horizontal